TIP767: Mastermind Discussion Q4 2025: Sanofi, Remitly & Crocs w/ Stig Brodersen, Tobias Carlisle, and Hari Ramachandra

What It Covers

Stig Brodersen, Tobias Carlisle, and Hari Ramachandra pitch three undervalued stocks: Sanofi (pharmaceuticals), Remitly (digital remittances), and Crocs (footwear). Each presents valuation metrics, competitive advantages, risks, and growth prospects in current market conditions.

Key Questions Answered

• •Pharmaceutical Value Play: Sanofi trades at 16x PE with 4.9% dividend yield versus peers at 25x PE, offering wealth preservation with 7-10% annual returns. The company generates recurring vaccine revenue similar to SaaS models, has diversified revenue beyond single blockbuster drugs, and benefits from euro-based operations providing dollar hedge protection.
• •Remittance Market Opportunity: Remitly captures 3% of $2 trillion remittance market with 30%+ revenue growth, 2.24% take rate, and under 12-month customer payback period with 6x lifetime value ratio. The company serves unbanked populations through local payment infrastructure like GCash in Philippines, creating competitive moat against both traditional services and stablecoin alternatives.
• •Footwear Turnaround Candidate: Crocs generates $900 million free cash flow on $4.3 billion market cap (6x earnings), trades at $79 versus $180 peak, and maintains 58% gross margins despite tariff concerns. The company authorized $1.3 billion buyback (25% of market cap) while growing 9% annually with 16% international growth and 64% China expansion.
• •Healthcare Sector Dislocation: Healthcare and pharmaceutical stocks trade at cheapest valuations relative to S&P 500 since 2000, creating opportunities in non-cyclical businesses with consistent cash flows. Capital flows concentrate in AI and Mag Seven stocks, leaving quality healthcare businesses undervalued despite subscription-like revenue models and regulatory moats protecting market positions.
• •Fashion Risk Assessment: Consumer brands like Crocs face faddish demand risk despite strong current metrics, requiring active monitoring rather than buy-and-hold approach. The company previously traded as net-net during fashion downturns, recovered through focusing on core clog product, but recently made $2.5 billion Hey Dude acquisition that required $700 million impairment, raising capital allocation concerns.